Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2005
06/09/2005WO2005051919A1 Aminopyrazole derivatives as gsk-3 inhibitors
06/09/2005WO2005051917A1 Pyrazolyl derivatives in the form of drugs for treating acute or chronic neuronal regressions
06/09/2005WO2005051914A1 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
06/09/2005WO2005051913A1 Cyclic amine derivative having heteroaryl ring
06/09/2005WO2005051912A1 Piperidine compound and method for producing same
06/09/2005WO2005051906A2 Heterocyclic inhibitors of mek and methods of use thereof
06/09/2005WO2005051903A1 Vitamin d-derived monohalogenovinyl compounds
06/09/2005WO2005051896A1 Nitroso derivatives of diphenylamine
06/09/2005WO2005051895A1 Organic compounds
06/09/2005WO2005051894A1 Novel salicylic anilides
06/09/2005WO2005051891A1 Use of cyclopropenylsphingosine derivatives for the production of a ceramidase activity-modulating pharmaceutical composition, and applications thereof
06/09/2005WO2005051511A1 Method for producing fine organic compound particles
06/09/2005WO2005051489A2 Fast dissolving solid oral dosage forms of galanthamine
06/09/2005WO2005051488A1 Combination of dopamine agonists and monoamine reuptake inhibitors
06/09/2005WO2005051485A1 Peptidically buffered formulations for electrotransport applications and methods of making
06/09/2005WO2005051484A1 Methods for preparing polymeric buffer formulations for electrotransport applications
06/09/2005WO2005051456A2 Composition and apparatus for transdermal delivery
06/09/2005WO2005051433A1 Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
06/09/2005WO2005051426A1 Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
06/09/2005WO2005051411A1 Novel drug: oxachelin and its derivatives
06/09/2005WO2005051410A1 Hepatitis c virus inhibitors
06/09/2005WO2005051406A1 Ceramidase inhibitor
06/09/2005WO2005051405A1 Il-8 production promoters and use thereof
06/09/2005WO2005051404A1 Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases
06/09/2005WO2005051403A1 Composition and method
06/09/2005WO2005051402A1 T-type calcium channel inhibitor
06/09/2005WO2005051401A2 Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
06/09/2005WO2005051400A1 Extended use combination comprising estrogens and progestins
06/09/2005WO2005051396A2 Methods for reducing body fat using vitamin d compounds
06/09/2005WO2005051395A1 (+) - (2s, 3s) -2- (3-chlorophenyl) -3, 5, 5-trimethyl-2-morpholinor for treating anxiety
06/09/2005WO2005051393A1 Method of treatment of atherosclerosis
06/09/2005WO2005051392A1 Gtpase inhibitors and methods of use
06/09/2005WO2005051391A1 Quinazolinone compounds with reduced bioaccumulation
06/09/2005WO2005051390A1 E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain
06/09/2005WO2005051389A1 Using of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate in the treatment of memory disorders
06/09/2005WO2005051388A1 Compositions and methods useful for treatment of conjunctivitis
06/09/2005WO2005051387A1 Amino substituted pyridinyl methanone compounds useful in treating kinase disorders
06/09/2005WO2005051386A1 Hmg-coa reductase inhibitors and method
06/09/2005WO2005051385A1 Substituted heterocycles useful for treating hcv infection
06/09/2005WO2005051384A1 Stabilised pharmaceutical compositions
06/09/2005WO2005051383A1 Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
06/09/2005WO2005051382A1 Agent enhancing lipid-loewring effect
06/09/2005WO2005051381A1 Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R)
06/09/2005WO2005051379A1 Tubular proteinuria as an indicator for elevated cardiovascular risk
06/09/2005WO2005051378A1 Method and composition for treating neurodegenerative disorders
06/09/2005WO2005051377A1 Use of schisandrin b for the manufacture of medicaments for treating diseases of tumors
06/09/2005WO2005051376A1 Medicaments containing collybolides
06/09/2005WO2005051375A1 Use of c-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorders
06/09/2005WO2005051374A1 Tablets of citalopram hydrobromide
06/09/2005WO2005051373A1 Receptor function regulating agent
06/09/2005WO2005051372A2 Method of purifying pravastatin
06/09/2005WO2005051371A1 Compositions and methods for treatment of cardiovascular disorders and diseases
06/09/2005WO2005051370A1 Composition having liver function protective effect
06/09/2005WO2005051369A1 Reversing, postponing or preventing the occurrence of gtn tolerance and/or generation of reactive oxygen species from mitochondria
06/09/2005WO2005051368A2 Phosphodiesterase v inhibitor formulations
06/09/2005WO2005051367A1 Carboxamide and amino derivatives and methods of their use
06/09/2005WO2005051362A2 Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
06/09/2005WO2005051361A1 Colonic purgative composition with soluble binding agent
06/09/2005WO2005051360A1 Pharmaceutical compositions comprising nateglinide and a surfactant
06/09/2005WO2005051359A1 Macromolecular drug complexes having improved stability and therapeutic use of the same
06/09/2005WO2005051356A1 Novel nimesulide compositions
06/09/2005WO2005051354A1 Controlled food effect composition
06/09/2005WO2005051353A2 Pharmaceutical formulations comprising voriconazole
06/09/2005WO2005051352A1 Veterinary compositions for treating mastitis
06/09/2005WO2005051350A2 Water dispersible tablet
06/09/2005WO2005051349A2 Pharmaceutical compositions of mirtazapine
06/09/2005WO2005051348A2 Enteric-coated tablets of pantoprazole
06/09/2005WO2005051346A2 Compositions comprising organic compounds
06/09/2005WO2005051345A1 Tirofiban for inhalative administration for the treatment of diseases that are caused by thrombosis
06/09/2005WO2005051344A2 Oral solid instant-release dosage forms comprising finasteride and an anionic surfactant-methods of manufacturing thereof
06/09/2005WO2005051342A1 Antimicrobial compositions containing an aromatic carboxylic acid and a hydric solvent
06/09/2005WO2005051331A2 Chaperone-based therapy for niemann-pick disease
06/09/2005WO2005051328A2 Amelioration of macular degeneration and other ophthalmic diseases
06/09/2005WO2005051323A2 Vitamin d analogs for obesity prevention and treatment
06/09/2005WO2005051322A2 Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
06/09/2005WO2005051321A2 Treatment of inflammatory bowel disease through induction of indoleamine 2,3-dioxygenase
06/09/2005WO2005051318A2 Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
06/09/2005WO2005051317A2 Substituted imidazo ring systems and methods
06/09/2005WO2005051308A2 Methods of treating diseases and disorders by targeting multiple kinases
06/09/2005WO2005051304A2 Akt protein kinase inhibitors
06/09/2005WO2005051302A2 Bicyclic inhibitors of mek and methods of use thereof
06/09/2005WO2005051301A2 Heterocyclic inhibitors of mek and methods of use thereof
06/09/2005WO2005051300A2 Bicyclic inhibitors of mek and methods of use thereof
06/09/2005WO2005051298A2 Novel phosphorus-containing thyromimetics
06/09/2005WO2005051297A2 Combination drug therapy to treat obesity
06/09/2005WO2005051296A2 Fused ring dicationic anti-protozoan agents and their prodrugs
06/09/2005WO2005051293A2 Methods and reagents for the treatment of inflammatory disorders
06/09/2005WO2005051290A2 Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone
06/09/2005WO2005051286A2 Stable ready-for-use injectable solution of 9-((1,3-dihydroxypropan-2-yloxy) methyl)-2-amine-1h-purin-6(9h)-one.
06/09/2005WO2005051092A2 Method of decreasing fat deposits and body weight in mammals and birds
06/09/2005WO2005042518A3 Substituted heterocyclic compounds and methods of use
06/09/2005WO2005042476A3 Prodrugs of diaryl-2-(5h)-furanone cyclooxygenase-2 inhibitors
06/09/2005WO2005040142A9 Novel keto-oxadiazole derivatives as cathepsin inhibitors
06/09/2005WO2005039552A3 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives
06/09/2005WO2005039489A3 Compositions and methods for the inhibition of bone growth and resorption
06/09/2005WO2005037836A3 Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors
06/09/2005WO2005037318A3 Treatment of arthritic conditions, chronic inflammation or pain
06/09/2005WO2005037198A3 Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
06/09/2005WO2005035537A3 Substituted tricyclic heterocycles and their uses
06/09/2005WO2005034919A3 Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component
1 ... 4658 4659 4660 4661 4662 4663 4664 4665 4666 4667 4668 4669 4670 4671 4672 4673 4674 4675 4676 4677 4678 ... 7860